^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1174P - The MET inhibitor ABN401 in combination with the third-generation EGFR-TKI is effective MET-amplified and EGFR-mutant NSCLC with acquired resistance to third-generation EGFR-TKI in preclinical models

Published date:
09/05/2022
Excerpt:
The signal transduction inhibition and cytotoxic response of ABN401 in combination with Lazertinib were tested in vitro against Osimertinib-resistance NSCLC cell lines (HCC827-AR) and patient-derived organoid (YUO-010)....ABN401 showed preclinical anti-tumor activities combined with Lazertinib (a 3rd-generation EGFR-TKI) in an EGFR mutant NSCLC model with MET gene amplification both in vitro and in vivo.